This order amends a prior executive order regarding duties on goods from China related to synthetic opioids. It modifies duty-free treatment eligibility based on the Secretary of Commerce's assessment of tariff collection systems. It affirms existing authorities and budgetary processes and clarifies it doesn't create enforceable rights.